Report Back From ASCO 2024: What’s the Latest in HR+ MBC?
Living with MBC, Diagnosis and Treatment, Clinical Research, Research, ASCO Our MBClife Living with MBC, Diagnosis and Treatment, Clinical Research, Research, ASCO Our MBClife

Report Back From ASCO 2024: What’s the Latest in HR+ MBC?

We are thrilled to present an audio version of SHARE Cancer Support’s webinar “Report Back from ASCO 2024: Latest Updates on HR+ Metastatic Breast Cancer (MBC)”.

This episode is an in-depth report from the ASCO 2024 Annual Meeting, featuring the latest advancements and research in HR+ MBC. Hear from Dr. Kevin Kalinsky as we dive into the findings from the DESTINY-Breast06 and postMONARCH trials, exploring their implications and potential impact on treatment strategies.

Read More
ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?
Novel Treatments, Medical Community, Diagnosis and Treatment, Clinical Research, Updates from Conferences, Entities of Cancer Our MBClife Novel Treatments, Medical Community, Diagnosis and Treatment, Clinical Research, Updates from Conferences, Entities of Cancer Our MBClife

ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?

Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.

Read More